April 23, 2018April 23, 2018

Epstein-Barr Virus May Increase Risk of MS, Other Diseases, Study Reports

News

Infection with the common Epstein-Barr virus (EBV) may increase the risk of developing multiple sclerosis (MS), a new report from the  Cincinnati Children’s Hospital Medical Center says. Besides ... Read more

April 23, 2018April 23, 2018

#AAN2018 – Blood Stem Cell Transplant Superior to DMDs in Highly Active RRMS, MIST Trial Shows

Alexa, News

Autologous non-myeloablative hematopoietic stem cell transplant was found to be significantly better at reducing risks for disability in relapsing-remitting multiple sclerosis patients compared to disease-modifying drug ... Read more

April 23, 2018April 23, 2018

#AAN2018 – Neurofilament Light Blood Levels Can Help Define Disease Activity in RRMS, Study Shows

News

Analysis of a potential blood biomarker linked to brain cell damage can help define disease activity in patients with relapsing-remitting multiple sclerosis (RRMS). Results of a ... Read more

April 20, 2018April 20, 2018

#AAN2018 – Ocrevus Data Support Sustained Efficacy, Ability to Aid Cognition in RMS Patients

News

Treatment with Ocrevus (ocrelizumab) shows sustained efficacy and an ability to improve cognition in patients with relapsing multiple sclerosis (MS), according to data being presented by Genentech, ... Read more

April 20, 2018April 20, 2018

#AAN2018 – Switching from Rebif to Ocrevus Improves MS, Extension Study Shows

News

Continuous treatment with Ocrevus (ocrelizumab) or switching from Rebif (interferon beta-1a) to Ocrevus leads to a significant long-term reduction in relapsing multiple sclerosis activity, a two-year extension study ... Read more

April 19, 2018April 19, 2018

#AAN2018 – Biogen Data Covers Work into an MS Blood Biomarker, Cognition and Life Quality

News

Research that points to a potential blood biomarker of multiple sclerosis (MS) severity, relates cognitive difficulties to patients’ employment and other measures of socioeconomic status, and one-year results ... Read more

April 19, 2018April 19, 2018

#AAN2018 — Investigational Therapy Ibudilast Slows Brain Atrophy in Phase 2 Trial for Progressive MS

News

Investigational therapy ibudilast leads to a significant reduction of brain atrophy, supporting its potential to effectively treat progressive multiple sclerosis (MS), new data from a Phase 2 clinical ... Read more

April 18, 2018April 18, 2018

#AAN2018 – Levels of Protein Derived from Brain Cell Damage Can Mirror Severity of MS, Study Finds

News

Levels of a protein stemming from brain cell damage can mirror the severity and symptoms of multiple sclerosis, an analysis of combined data from three trials ... Read more

April 18, 2018April 18, 2018

#AAN2018 — Early Treatment Delays MS Disease Progression But Does Not Affect Death Rate, Study Suggests

News

Beginning treatment early with disease-modifying therapies is the most effective approach to prevent multiple sclerosis (MS) progression in patients, a large-scale study suggests. Data from the ... Read more

April 18, 2018April 18, 2018

#AAN2018 – Ocrevus Decreases Biomarkers of MS Patients’ Nerve Cell Damage, Phase 3 Trial Shows

News

Genentech’s Ocrevus (ocrelizumab) reduces levels of cerebrospinal fluid biomarkers that denote nerve cell damage in multiple sclerosis patients, a Phase 3 clinical trial shows. Researchers will present the ... Read more

April 17, 2018April 17, 2018

5 MS Patients Across US Talk About How Ocrevus Has Changed Their Lives

News

It’s been a little over a year since U.S. regulators approved Genentech’s Ocrevus (ocrelizumab) as the first treatment for both relapsing and progressive forms of multiple sclerosis (MS) ... Read more

April 17, 2018April 17, 2018

#AAN2018 – Siponimod Reduces Disease Activity Biomarker in SPMS Patients

News

Novartis‘ siponimod (BAF312) can reduce blood levels of a biomarker of nerve cell damage in patients with secondary progressive multiple sclerosis (SPMS), a Phase 3 clinical ... Read more

April 16, 2018April 16, 2018

SPMS Patients Have More Cognitive Decline Than Those with RRMS, Study Reports

News

People with secondary progressive multiple sclerosis (SPMS) have more cognitive decline than those with relapsing-remitting MS (RRMS), according to a Greek study. The finding confirmed a ... Read more

April 16, 2018April 17, 2018

Adverse Effects Influence Patient’s Perspective of Ocrevus’s Effectiveness, Survey Shows

News

Higher rates of adverse effects have a negative impact on a patient’s perspective about treatment with Ocrevus (ocrelizumab), according to a survey conducted by the multiple sclerosis community GeneFo. ... Read more

April 13, 2018April 13, 2018

Acute Acalculous Cholecystitis Linked to Lemtrada Use in RRMS Patients, FDA Reports

News

Acute acalculous cholecystitis (AAC) is a rare but potentially life-threatening adverse effect linked to treatment with Lemtrada (alemtuzumab) in patients with relapsing-remitting multiple sclerosis (RRMS), according to ... Read more

April 13, 2018April 13, 2018

MS Foundation Partnering with ThermApparel to Provide Cooling Vests to Patients

News

The MS Focus: Multiple Sclerosis Foundation will be accepting applications through June for its Cooling Program, which provides cooling garments to multiple sclerosis patients whose condition has left them heat-sensitive. ... Read more

April 12, 2018April 12, 2018

First Generation Disease-modifying Therapies Pose Low Infection Risk in MS, Study Finds

News

A large group study showed that first-generation disease-modifying therapies (DMTs) do not increase the infection risk in multiple sclerosis (MS) patients. Many of the DMTs used ... Read more

April 12, 2018April 12, 2018

US, Australia Issue Patents on Sonde’s Voice-analysis Technology for Diagnosing Diseases

News

The United States and Australia have issued patents on Sonde Health‘s voice-analysis technology for diagnosing and monitoring multiple sclerosis and other diseases that affect speech. Sonde, which has ... Read more